Safety and Efficacy of NeuroFlo Technology In Ischemic Stroke (SENTIS)
Safety and Efficacy of NeuroFlo Technology In Ischemic Stroke (SENTIS): A Study of Care Intensity and Outcomes of Neuroflo® (SCION) To compare treatment for ischemic stroke outcome with NeuroFlo plus standard medical management vs. standard medical management alone. Enrollment : 244 patients at 80 US sites, aged 18 years and older, diagnosed with a focal neurological deficit due to ischemia, with a baseline NIHSS between 5 and 18, in whom the NeuroFlo procedure will begin within 14 hours of symptom onset in those patients randomized to treatment.
August 01, 2005
W. Scott Burgin, MD
Cheryl Weber, RN, MS, CCRC